Hot Flushes: What Actually Works, Ranked by Evidence

HerWellReport is reader-supported. We may earn a commission from links on this page at no extra cost to you — see our affiliate disclosure. This article is information, not medical advice; please read our medical disclaimer.

Search for help with hot flushes, or hot flashes as they are more often called in the US, and you will get a list: hormone therapy, black cohosh, cooling sprays, yoga, breathing exercises, a supplement with a nice bottle. Presented flat, as though they were roughly comparable options.

They are not remotely comparable. There is a real evidence hierarchy here, and it is uncomfortable in both directions — some of the gentlest-sounding advice is formally recommended against for flushes specifically, and the whole over-the-counter supplement category, including the one this site reviews, is not recommended by the leading menopause body. Here is the ranking, with the sources.

What a hot flush actually is

Vasomotor symptoms occur in up to 80% of menopausal women, with a mean duration of 7 to 9 years, and in about a third of women they last more than 10 years.¹

The best longitudinal figures come from the Study of Women’s Health Across the Nation. Among 1,449 women with frequent vasomotor symptoms, median total duration was 7.4 years, and among those with an observable final period, symptoms persisted a median of 4.5 years afterwards.² Who gets them longest is not random: women whose symptoms began in premenopause or early perimenopause had a median duration exceeding 11.8 years, while women whose symptoms started after the final period had a median of 3.4 years. Black women in that cohort reported the longest median duration, 10.1 years. Longer duration was also associated with younger age at onset, greater perceived stress and higher symptom sensitivity — associations within an observational cohort, not causes.²

Physiologically, the body normally tolerates a small band of core temperature without sweating or shivering. In women with hot flushes that band has effectively collapsed: measured at 0.0°C in symptomatic postmenopausal women against 0.4°C in asymptomatic women, mainly because the sweating threshold has dropped. Most flushes were preceded by small but statistically significant rises in core temperature, and central sympathetic activation appears to play a part in setting them off.³ That is why a flush feels like it arrives from nowhere — the margin for error has gone.

The newer piece of the picture is hypothalamic. As the approved labelling for one of the new drugs puts it, fezolinetant blocks neurokinin B binding on the KNDy neuron to modulate activity in the thermoregulatory centre.⁴ Practically: falling oestrogen releases the brake on a specific set of hypothalamic neurons that signal into the body’s thermostat, and blocking that signal reduces flushes without touching oestrogen at all.

Tier 1: Hormone therapy

The Menopause Society’s position is that hormone therapy remains the most effective treatment for vasomotor symptoms and for the genitourinary syndrome of menopause.⁵ NICE says: offer women HRT for vasomotor symptoms after discussing the short-term and longer-term benefits and risks.⁶

The timing matters. The benefits outweigh the risks for most healthy symptomatic women aged under 60 and within 10 years of menopause onset, with risk stratification by age and time since menopause recommended and periodic reassessment built in.⁵⁷ Transdermal routes and lower doses may reduce the risk of venous thromboembolism and stroke.⁵ For women with premature ovarian insufficiency, hormone therapy is indicated until at least the average age of menopause unless there is a contraindication.⁵

It is not for everyone. The Menopause Society’s patient guidance states that women with breast cancer, uterine cancer, unexplained uterine bleeding, liver disease, a history of blood clots or cardiovascular disease should not use hormone therapy.⁷

The recent regulatory change, accurately. In November 2025 the US Food and Drug Administration announced it was initiating removal of boxed warnings from systemic menopausal hormone therapy products, noting that the original warnings rested on a Women’s Health Initiative finding of a statistically non-significant breast cancer increase, in a cohort averaging 63 years of age, using a formulation no longer in common use. The boxed warning for endometrial cancer on oestrogen-alone systemic products was not removed.⁸ In February 2026 the FDA approved labelling changes across six products removing cardiovascular disease, breast cancer and probable dementia risk statements from the boxed warning.⁹

The Menopause Society welcomed the change for low-dose vaginal oestrogen, noting the warning may have deterred use of a safe and effective therapy, while stressing that systemic oestrogen therapies still carry risks requiring individual assessment by age, health status, symptom severity and preference.¹⁰ A label change is a change in how risk is communicated. It is not a finding that risk is zero — and the Society’s own hormone therapy position statement still dates from 2022, before any of this.¹¹

Tier 2: Non-hormonal prescription options

The Menopause Society’s 2023 nonhormone therapy position statement recommends: cognitive-behavioural therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant at Level I evidence; oxybutynin at Levels I–II; weight loss and stellate ganglion block at Levels II–III.¹

Fezolinetant and elinzanetant — the new class

Fezolinetant (Veozah) is an NK3 receptor antagonist. In its pivotal trials, women starting from around 10 to 12 moderate-to-severe flushes a day saw reductions at week 12 of 6.4 and 7.5 per day, against 3.9 and 5.0 on placebo.⁴ Look closely at those placebo figures — that is the scale of response a bottle of anything can harvest without doing anything. A phase 3 trial reported improvement within one week, sustained across 52 weeks.¹²

In December 2024 the FDA added a boxed warning for rare but serious liver injury. Liver tests are required before starting, monthly for the first three months, then at months 6 and 9; it should not be started if transaminases or bilirubin are twice the upper limit of normal, and should be stopped at defined thresholds. Warning symptoms include fatigue, nausea, vomiting, unusual itching, light-coloured stools, jaundice, dark urine, abdominal swelling and right upper abdominal pain.¹³⁴

Elinzanetant (Lynkuet), approved in October 2025, blocks both NK1 and NK3 receptors and is taken at bedtime. Against placebo it reduced moderate-to-severe flush frequency by around 3.0 to 3.3 per 24 hours at weeks 4 and 12 across two trials. It also requires baseline liver testing and a repeat at three months, is contraindicated in pregnancy, and central nervous system effects — somnolence, fatigue, vertigo, dizziness — occurred in 11.9% of women against 3.5% on placebo.¹⁴ It is newer than the 2023 position statement, so the Society has not yet rated it.

Antidepressants, gabapentin, oxybutynin

SSRIs and SNRIs — paroxetine, escitalopram, citalopram, venlafaxine, desvenlafaxine — are associated with mild to moderate improvements, with reported hot flush reductions varying from 25% to 69%. Low-dose paroxetine at 7.5 mg showed improvement for up to 24 months alongside better sleep and without weight gain.¹ Gabapentin at 900 mg daily improved frequency and severity, and at 2,400 mg daily was as beneficial as oestrogen in reducing hot flush severity scores.¹ Oxybutynin at 2.5 to 15 mg daily significantly improved moderate to severe symptoms — with the honest caveat, stated in the position statement itself, that long-term anticholinergic use may be associated with cognitive decline, particularly in older people.¹

Worth naming a real transatlantic disagreement here: NICE says do not routinely offer SSRIs, SNRIs or clonidine as first-line treatment for vasomotor symptoms alone.⁶ Clonidine is on the Menopause Society’s not-recommended list too — modestly better than placebo, less effective than the alternatives, with significant adverse effects.¹

Tier 3: Behavioural approaches that do hold up

Cognitive behavioural therapy is recommended at Level I. The important nuance: it has been shown to reduce the bother and interference associated with vasomotor symptoms, with 65 to 78% of participants reaching clinically significant improvement across trials — the gain is largely in how much they disrupt your life, not necessarily in the count.¹ When NICE updated its menopause guideline in November 2024 it added menopause-specific CBT for vasomotor symptoms and sleep, either alongside HRT or as an alternative for women who decline or cannot take it.¹⁵

Clinical hypnosis is the most underrated item on the entire list. It is recommended at Level I, with one trial showing significantly lower hot flush frequency versus attention control at 12 weeks — 74% against 17%.¹ Independent US government health information notes NIH-funded research finding hypnotherapy reduced hot flush frequency.¹⁶

Weight loss is recommended at Levels II–III on limited evidence, and appears particularly effective earlier in the transition.¹

Tier 4: Supplements and botanicals

Here is the category verdict, in the Menopause Society’s own words: “Given the lack of rigorous, evidence-based scientific research supporting the use of any over-the-counter supplements and herbal therapies for the management of VMS, these remedies are not recommended.”¹ Listed as not recommended at Levels I–II, alongside named botanicals including black cohosh, wild yam, dong quai, evening primrose, maca, ginseng, chasteberry, milk thistle, omega-3 fatty acids and vitamin E.¹

We monetise this site partly through a menopause supplement, and we are still telling you that. The reasoning is set out in our menopause supplements guide.

• Black cohosh. A Cochrane review of 16 randomised trials found insufficient evidence; a 2016 meta-analysis found no significant association with reduced vasomotor symptoms; two high-quality trials showed no advantage over placebo.¹⁷ It also carries the strongest safety signal in the category: NIH’s LiverTox gives it a likelihood score of A for clinically apparent liver injury, with more than 50 reported cases including acute liver failure requiring transplant and death, although causality remains contested and contamination with other species is implicated in some cases.¹⁸ There have been at least 83 global reports of liver damage; Australia requires a label warning.¹⁷
• Red clover. Cochrane pooled five trials: mean difference in daily hot flush frequency of −0.93, with a 95% confidence interval of −1.95 to 0.10 — an interval that crosses zero, meaning no significant difference.¹⁹
• Soy isoflavones. Cochrane, across 43 randomised trials: no conclusive evidence that phytoestrogen supplements effectively reduce the frequency or severity of hot flushes and night sweats. One open question remains — trials of extracts delivering more than 30 mg/day of genistein consistently reduced flush frequency and warrant further investigation.¹⁹ The Menopause Society does not recommend soy foods, soy extracts or the soy metabolite equol.¹
• Evening primrose and dong quai. Very little research has been done on either for menopausal symptoms, so no conclusions can be drawn; dong quai may interact with warfarin.¹⁶
• Maca. Four randomised trials; the systematic review concluded the total sample size and methodological quality were too limited to draw firm conclusions.²⁰
• Vitamin E. Not recommended; limited evidence with small effects, and it may increase bleeding risk and interact with blood-thinning medication.¹¹⁶
• Ashwagandha and sage. Neither appears in the 2023 position statement at all. We have gone through the ashwagandha evidence in detail in does ashwagandha help menopause symptoms. On sage, the most-cited meta-analysis pooled four studies in 310 women and reported a frequency effect size of −1.12 with a 95% confidence interval of −2.37 to 0.14 — an interval crossing zero, with high heterogeneity, despite the authors describing it as significant.²¹ Check the interval, not the conclusion.

NICE takes a gentler line worth reporting for balance: there is some evidence that isoflavones or black cohosh may relieve vasomotor symptoms, but multiple preparations are available, their safety is uncertain, different preparations may vary, interactions have been reported, and the quality, purity and constituents of products may be unknown.⁶

What is formally recommended against — including things you would not expect

This is the section that surprises people. The 2023 position statement recommends against the following for vasomotor symptoms:¹

• Paced respiration (Level I) — unlikely to provide any benefit; larger trials found it no better than shallow breathing or usual care.
• Cooling techniques, avoiding triggers, exercise, yoga, mindfulness-based intervention, relaxation (Level II).
• Acupuncture (Level II) — traditional acupuncture shows little to no clinical benefit compared with sham, though electroacupuncture warrants further investigation.
• Supplements and herbal remedies (Levels I–II), soy foods and extracts and equol, cannabinoids, dietary modification, pregabalin, suvorexant, chiropractic interventions and clonidine.

Read that carefully, because it is easy to misread. “Not recommended for vasomotor symptoms” means the intervention does not reduce hot flushes in trials. It does not mean exercise and yoga are worthless — independent NIH health information records yoga reducing physical and psychological menopausal symptoms more broadly, and mindfulness reducing how much hot flushes bother women without changing their intensity.¹⁶ Keep doing them. Just do not expect them to cut the flush count.

The paced-breathing story is instructive in its own right. An earlier review reported roughly 50% reductions in objectively measured flushes across three controlled studies.³ The larger trials that followed did not replicate it.¹ That is exactly why small early trials should not settle a question — a lesson that applies just as forcefully to the supplement aisle.

The placebo problem, and why testimonials mean nothing here

Cochrane recorded placebo-arm hot flush reductions ranging from 1% to 59% across phytoestrogen trials.¹⁹ Read that again. In the placebo groups. Any uncontrolled before-and-after, any self-reported 30-day result, any glowing testimonial sits comfortably inside that range without the product having done anything at all.

This is the single best reason to be sceptical of a supplement’s own evidence page, and the reason we do not publish testimonials on this site.

That is also the practical argument for writing it down. If the placebo response is this large, “it feels a bit better” is not evidence you can act on, and it is not something a clinician can do much with either. Counting flushes by severity for a week or two turns an impression into something you can actually judge — and moderate-to-severe episodes per day is the figure the trials above are built on. Our free 7-day menopause journal grades them using the definitions the FDA sets out for menopause trials, works out your weekly averages, and prints a one-page summary you can take to an appointment. No sign-up, and nothing you type leaves your own browser.

Common questions

What actually works best?

Systemic hormone therapy — described by The Menopause Society as the most effective treatment for vasomotor symptoms, and recommended by NICE after a benefits-and-risks discussion.⁵⁶ If it is unsuitable or unwanted, the strongest non-hormonal options are fezolinetant and elinzanetant, SSRIs and SNRIs, gabapentin and oxybutynin, plus CBT and clinical hypnosis.¹⁴¹⁴

How long will they last?

In the SWAN cohort, median total duration of frequent vasomotor symptoms was 7.4 years, with a median 4.5 years continuing after the final period.² The Menopause Society gives a mean of 7 to 9 years, more than 10 years in about a third of women.¹ Women whose symptoms start earliest have the longest course.²

Does black cohosh work?

The best evidence says no clear benefit — a Cochrane review of 16 trials found insufficient evidence, and a 2016 meta-analysis found no significant reduction.¹⁷ It is not recommended by The Menopause Society,¹ and it carries a documented liver-injury signal.¹⁸

Is there a non-hormonal prescription that is not an antidepressant?

Yes, two. Fezolinetant blocks neurokinin B signalling in the brain’s thermoregulatory centre; in its pivotal trials it reduced moderate-to-severe flushes by 6.4 and 7.5 a day at week 12 against 3.9 and 5.0 on placebo, and it carries a boxed warning for rare serious liver injury with a defined monitoring schedule.⁴¹³ Elinzanetant, approved in October 2025, blocks both NK1 and NK3 receptors and is taken at bedtime.¹⁴

Will cooling, trigger-avoidance and breathing exercises help?

For comfort and a sense of control, possibly. For reducing the flushes themselves, the 2023 position statement recommends against paced respiration, cooling techniques, trigger avoidance, exercise, yoga, relaxation and mindfulness for vasomotor symptoms specifically.¹ What does hold up behaviourally is CBT and clinical hypnosis.¹¹⁵

Do hot flushes have anything to do with cortisol?

The mechanism established in the regulatory and physiological literature is hypothalamic and thermoregulatory, not adrenal.⁴³ No cortisol-targeting intervention appears among the recommended therapies in the 2023 position statement.¹ We looked at the cortisol claim in detail in cortisol and menopause.

Bottom line

Hormone therapy is the most effective treatment and, for most healthy women under 60 and within ten years of menopause, the benefits outweigh the risks. If it is not for you, there are now two new drug classes plus antidepressants, gabapentin and oxybutynin, and two behavioural approaches — CBT and clinical hypnosis — with Level I evidence behind them. Cooling, trigger avoidance, yoga and paced breathing are formally not recommended for the flushes themselves, though they may be worth doing for other reasons. And the entire over-the-counter supplement category is not recommended by the leading menopause body, which is worth knowing before you spend money on one. If your flushes are wrecking your nights as well as your days, our piece on perimenopause and your bladder covers the other thing that tends to be waking you. And if it is the sleep itself that has come apart, our sister site’s guide to menopause and sleep works through why menopausal nights break — vasomotor symptoms, hormones, rising apnoea risk, the bladder — and makes the useful point that dense memory foam retains heat and is worth avoiding if you sweat at night.

This article is for information only and is not medical advice. Hormone therapy and the prescription options described here are decisions for you and your doctor.

More from HerWellReport

• Menopause supplements: what is actually in them
• Cortisol and menopause: what the evidence really shows
• Does ashwagandha help menopause symptoms?
• Perimenopause and your bladder: the oestrogen link
• MenoRescue ingredients: the full list, doses and interactions
• Is MenoRescue a scam? An honest answer
• Nature’s Way AM/PM PeriMenopause Formula: An Honest Ingredient Review
• One A Day Women’s Menopause Formula: An Honest Ingredient Review
• Happy Mammoth Hormone Harmony Review